EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of bevacizumab in combination with chemotherapy in metastatic colorectal cancer — a single-center real-world analysis

Jovana Trifunović, Sara Filipović, Nemanja Trifunović, Marina Stojanović, Sofija Milanović

Taurunum Medical Journal · 2025

DOI: 10.63696/tmj202502184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Taurunum Medical Journal, 2025. Verfasst von Jovana Trifunović und 4 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

<p>Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), represents an important component of systemic therapy for metastatic colorectal cancer (mCRC). By inhibiting angiogenesis and promoting vascular normalization, bevacizumab enhances the efficacy of cytotoxic drugs. However, despite proven benefits, some uncertainties remain regarding its safety profile, particularly the risk of gastrointestinal perforation and other vascular toxicities. Materials and Methods: This retrospective, single-center, observational study included patients with histologically confirmed mCRC treated with combination chemotherapy and bevacizumab (FOLFOX/FOLFIRI + bevacizumab) at the Oncology Department of Zemun Clinical Hospital Center between July 2022 and July 2025. Efficacy was assessed according to RECIST 1.1 criteria, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and duration of response (DoR). Adverse events were classified according to CTCAE v6.0.

Results

A total of 74 patients were analyzed (56.8% male; mean age 67 &plusmn; 9 years). The median PFS was 6.5 months (IQR 3&ndash;9.8), and DoR 7.3 months (95% CI 5.2&ndash;9.5). ORR was 35.1%, and DCR 82.4%. The most common toxicities were hypertension (12.2%) and proteinuria (10.9%), while gastrointestinal perforation was observed in 4.1% of patients&mdash;slightly higher than in larger real-world series, which may be related to locally advanced disease, peritoneal carcinomatosis, or an intact primary tumor.

Conclusion

Bevacizumab-based therapy demonstrated consistent efficacy and an acceptable safety profile in patients with mCRC. Although the incidence of perforation and fistula formation was somewhat higher, the therapy remained safe with careful patient selection and monitoring.</p>

Zitieren

APA

Trifunović, J., Filipović, S., Trifunović, N., Stojanović, M., & Milanović, S. (2025). Efficacy and safety of bevacizumab in combination with chemotherapy in metastatic colorectal cancer — a single-center real-world analysis. Taurunum Medical Journal. https://doi.org/10.63696/tmj202502184

Vancouver

Trifunović J, Filipović S, Trifunović N, Stojanović M, Milanović S. Efficacy and safety of bevacizumab in combination with chemotherapy in metastatic colorectal cancer — a single-center real-world analysis. Taurunum Medical Journal. 2025. doi:10.63696/tmj202502184

BibTeX
@article{Trifunovi2025,
  author = {Trifunović, Jovana and Filipović, Sara and Trifunović, Nemanja and Stojanović, Marina and Milanović, Sofija},
  title = {Efficacy and safety of bevacizumab in combination with chemotherapy in metastatic colorectal cancer — a single-center real-world analysis},
  journal = {Taurunum Medical Journal},
  year = {2025},
  doi = {10.63696/tmj202502184}
}
Kostenlos starten →